Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 563
Filter
1.
Int J Mol Sci ; 25(19)2024 Sep 28.
Article in English | MEDLINE | ID: mdl-39408787

ABSTRACT

Bloodstream infection is one of the most important and increasing complications in patients with severe burns. Most of the species affecting this population are Gram-negative bacilli that exhibit antimicrobial resistance. We conducted this study to determine the antimicrobial susceptibility profile and resistance mechanisms of these bacterial infections and their clinical associations on morbidity and mortality. We analyzed a retrospective cohort of burn patients. All patients included in this study had monobacterial blood stream infections during their hospital stay. We performed phenotypic and genotypic tests to determine the antimicrobial resistance mechanism and profile of each strain. Univariate and multivariate logistic regression analysis was performed between variables. We found 109 patients with monobacterial bacteremia. Pseudomonas spp. (50.7%), A. baumannii (46.4%), and Klebsiella spp. (13.8%) were the most common causative microorganisms. The Pseudomonas spp. isolates showed resistance to imipenem (81.5%), mainly by class A and class B carbapenemases. The A. baumannii isolates conferred resistance to imipenem (56.2%), mainly by class D carbapenemases. One quarter of Klebsiella spp. showed resistance to 3rd generation cephalosporins. We also observed that a total body surface area greater than 40% and three or more different types of invasive procedures might be related to increased mortality. Multidrug resistance is highly present. The extent of the burned area and a high number of different types of invasive procedures had an impact in decreasing survivorship in burn patients with bacteremia.


Subject(s)
Anti-Bacterial Agents , Bacteremia , Burns , Humans , Burns/microbiology , Burns/complications , Male , Female , Bacteremia/microbiology , Bacteremia/drug therapy , Middle Aged , Adult , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Retrospective Studies , Microbial Sensitivity Tests , Gram-Negative Bacteria/drug effects , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/drug therapy , Aged , Drug Resistance, Multiple, Bacterial , Cohort Studies
2.
Future Microbiol ; 19(17): 1445-1454, 2024.
Article in English | MEDLINE | ID: mdl-39258398

ABSTRACT

Aim: Polymyxin B (PMB) is one of the few therapeutic options for treating infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB). However, the emergence of PMB-resistant CR-GNB strains has prompted the exploration of antibiotic adjuvants as potential therapeutic avenues. Thus, this study evaluates the potential of 3,5-dinitrobenzoic acid derivatives (DNH01, DNH11, DNH13 and DNH20) and isoniazid-N-acylhydrazones (INZ1-7, INZ9 and INZ11) as adjuvants to enhance PMB efficacy against CR-GNB.Materials & methods: MIC, MBC and drug combination assays were conducted using multidrug-resistant clinical isolates of Enterobacterales and Acinetobacter baumannii. In addition, the effects of PMB and PMB + DNH derivatives were assessed through flow cytometry and scanning electron microscopy (SEM).Results: DNH01, DNH11 and DNH20, unlike the INH-acylhydrazones, significantly restored PMB activity (MIC ≤ 2 µg/ml) in 80% of the tested isolates. Flow cytometry and SEM assays confirmed that DNH derivatives rescued the activity of PMB, yielding results comparable to those expected for PMB alone but at 256-fold lower concentrations.Conclusion: These findings suggest DNH derivatives hold substantial promise as PMB adjuvants to combat PMB-resistant CR-GNB infections.


[Box: see text].


Subject(s)
Anti-Bacterial Agents , Carbapenems , Gram-Negative Bacteria , Microbial Sensitivity Tests , Polymyxin B , Polymyxin B/pharmacology , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Carbapenems/pharmacology , Humans , Acinetobacter baumannii/drug effects , Drug Resistance, Multiple, Bacterial/drug effects , Adjuvants, Pharmaceutic/pharmacology , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/microbiology , Drug Synergism
3.
Front Cell Infect Microbiol ; 14: 1354736, 2024.
Article in English | MEDLINE | ID: mdl-39045133

ABSTRACT

The present study evaluated the capacity of three Bacillus species to improve health status and growth performance of Nile Tilapia fed with high levels of soybean meal and challenged with Aeromonas hydrophila. In vitro experiments showed that ß-hemolysin and metalloprotease enzymes were produced by A. hydrophila throughout the exponential growth phase. In vivo experiments showed that 107 colony-forming units (CFUs)/ml of this pathogen killed 50% of control group fishes in 13 days. To evaluate the influence of Bacillus strains on health status and growth performance in Nile Tilapia, 180 fishes (33.44 + 0.05 g) were distributed in 12 tanks of 200 L each, and animals were fed twice per day until satiety. 1) Control group without Bacillus, 2) Bacillus sp1, 3) Bacillus sp2, and 4) Bacillus sp3 groups were formulated containing 106 CFU/g. After 40 days of feeding, the fishes were intraperitoneally injected with 1 ml of A. hydrophila at 2 × 107 CFU/ml, and mortality was recorded. The results showed that cumulative mortality rate was significantly (p< 0.05) lower in the Bacillus sp1 (25%), sp2 (5%), and sp3 (15%) groups, than the control group (50%). Weight gain was also significantly better (p< 0.05) in the Bacillus sp1 (36%), sp2 (67%), and sp3 (55%) groups with respect to the control group (30%). In conclusion, functional diet formulated with high levels of soybean meal and supplemented with Bacillus sp2 could be an alternative to protect Nile tilapia cultures from A. hydrophila infections and improve fish growth performance.


Subject(s)
Aeromonas hydrophila , Bacillus , Cichlids , Fish Diseases , Gram-Negative Bacterial Infections , Animals , Fish Diseases/microbiology , Fish Diseases/prevention & control , Cichlids/growth & development , Cichlids/microbiology , Aeromonas hydrophila/pathogenicity , Aeromonas hydrophila/growth & development , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/veterinary , Gram-Negative Bacterial Infections/prevention & control , Animal Feed , Probiotics/administration & dosage , Glycine max/microbiology , Aquaculture
4.
Article in English | MEDLINE | ID: mdl-39082485

ABSTRACT

Stenotrophomonas maltophilia was considered to be a low-virulence organism. But it has emerged as a prominent opportunistic pathogen in patients with certain risk factors. This study aimed to describe an outbreak experienced in our hospital with all dynamics while evaluating previous S. maltophilia outbreak reports. S. maltophilia isolates were obtained from a university hospital in Türkiye in a seven-months period. Antimicrobial resistance, type of infections, predisposing factors of infected patients, antibiotic therapy, outcome of infections, and outbreak source were investigated. Also, S. maltophilia outbreaks in the literature were reviewed. In the 12 months prior to the outbreak, prevalence rate of clinical samples including S. maltophilia was 7/1,000 patient per day, opposed to 113/1,000 patient per day during the outbreak. Although a large number of cases were observed in a short seven-month period, a source of contamination could not be detected. Stable mortality rates (or remaining close to the average) during outbreaks can be attributed to the careful attention paid by laboratory and clinic physicians during procedures. S. maltophilia has potential to spread outbreaks and infect patients in operating rooms and intensive care units during invasive procedures.


Subject(s)
Cross Infection , Disease Outbreaks , Gram-Negative Bacterial Infections , Hospitals, University , Stenotrophomonas maltophilia , Stenotrophomonas maltophilia/isolation & purification , Stenotrophomonas maltophilia/drug effects , Humans , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology , Cross Infection/epidemiology , Cross Infection/microbiology , Risk Factors , Turkey/epidemiology , Male , Female , Anti-Bacterial Agents/pharmacology
5.
Microb Drug Resist ; 30(9): 354-362, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39029506

ABSTRACT

Background: Biofilm production in nonfermenting Gram-negative bacteria influences drug resistance. The aim of this work was to evaluate the effect of different antibiotics on biofilm eradication of clinical isolates of Achromobacter, Burkholderia, and Stenotrophomonas maltophilia. Methods: Clinical isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry in a third-level hospital in Monterrey, Mexico. Crystal violet staining was used to determine biofilm production. Drug susceptibility testing was determined by broth microdilution in planktonic cells and biofilm cells. Results: Resistance in planktonic cells was moderate to trimethoprim-sulfamethoxazole, and low to chloramphenicol, minocycline, levofloxacin (S. maltophilia and Burkholderia), ceftazidime, and meropenem (Burkholderia and Achromobacter). Biofilm eradication required higher drug concentrations of ceftazidime, chloramphenicol, levofloxacin, and trimethoprim-sulfamethoxazole than planktonic cells (p < 0.05). Levofloxacin showed biofilm eradication activity in S. maltophilia, minocycline and meropenem in Burkholderia, and meropenem in Achromobacter. Conclusions: Drug resistance increased due to biofilm production for some antibiotics, particularly ceftazidime and trimethoprim-sulfamethoxazole for all three pathogens, chloramphenicol for S. maltophilia and Burkholderia, and levofloxacin for Burkholderia. Some antibiotics could be used for the treatment of biofilm-associated infections in our population, such as levofloxacin for S. maltophilia, minocycline and meropenem for Burkholderia, and meropenem for Achromobacter.


Subject(s)
Achromobacter , Anti-Bacterial Agents , Biofilms , Burkholderia , Gram-Negative Bacterial Infections , Microbial Sensitivity Tests , Stenotrophomonas maltophilia , Biofilms/drug effects , Stenotrophomonas maltophilia/drug effects , Anti-Bacterial Agents/pharmacology , Humans , Burkholderia/drug effects , Achromobacter/drug effects , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/drug therapy , Drug Resistance, Bacterial , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology , Mexico , Ceftazidime/pharmacology , Plankton/drug effects , Drug Resistance, Multiple, Bacterial , Levofloxacin/pharmacology
6.
J Clin Microbiol ; 62(7): e0125523, 2024 Jul 16.
Article in English | MEDLINE | ID: mdl-38904386

ABSTRACT

Prompt and precise identification of carbapenemase-producing organisms is crucial for guiding clinical antibiotic treatments and limiting transmission. Here, we propose modifying the Blue Carba test (BCT) and Carba NP-direct (CNPd) to identify molecular carbapenemase classes, including dual carbapenemase strains, by adding specific Class A and Class B inhibitors. We tested 171 carbapenemase-producing Gram-negative bacilli strains-21 in Class A (KPC, NMC, SME), 58 in Class B (IMP, VIM, NDM, SPM), and 92 with dual carbapenemase production (KPC+NDM, KPC+IMP, KPC+VIM), all previously positive with BCT or CNPd. We also included 13 carbapenemase non-producers. ß-lactamases were previously characterized by PCR. The improved BCT/CNPd methods detect imipenem hydrolysis from an imipenem-cilastatin solution, using pH indicators and Class A (avibactam) and/or Class B (EDTA) inhibitors. Results were interpreted visually based on color changes. CNPd achieved 99.4% sensitivity and 100% specificity in categorizing carbapenemases, while BCT had 91.8% sensitivity and 100% specificity. Performance varied by carbapenemase classes: both tests classified all Class A-producing strains. For Class B, the CNP test identified 57/58 strains (98.3%), whereas the BCT test, 45/58 strains (77.6%), with non-fermenters posing the greatest detection challenge. For Classes A plus B dual producers, both tests performed exceptionally well, with only one indeterminate strain for the BCT. The statistical comparison showed both methods had similar times to a positive result, with differences based on the carbapenemase class or bacterial group involved. This improved assay rapidly distinguishes major Class A or Class B carbapenemase producers among Gram-negative bacilli, including dual-class combinations, in less than 2 hours. IMPORTANCE: Rapid and accurate identification of carbapenemase-producing organisms is of vital importance in guiding appropriate clinical antibiotic treatments and curbing their transmission. The emergence of negative bacilli carrying multiple carbapenemase combinations during and after the severe acute respiratory syndrome coronavirus 2 pandemic has posed a challenge to the conventional biochemical tests typically used to determine the specific carbapenemase type in the isolated strains. Several initiatives have aimed to enhance colorimetric methods, enabling them to independently identify the presence of Class A or Class B carbapenemases. Notably, no previous efforts have been made to distinguish both classes simultaneously. Additionally, these modifications have struggled to differentiate between carriers of multiple carbapenemases, a common occurrence in many Latin American countries. In this study, we introduced specific Class A and Class B carbapenemase inhibitors into the Blue Carba test (BCT) and Carba NP-direct (CNP) colorimetric assays to identify the type of carbapenemase, even in cases of multiple carbapenemase producers within these classes. These updated assays demonstrated exceptional sensitivity and specificity (≥ 90%) all within a rapid turnaround time of under 2 hours, typically completed in just 45 minutes. These in-house enhancements to the BCT and CNP assays present a rapid, straightforward, and cost-effective approach to determining the primary carbapenemase classes. They could serve as a viable alternative to molecular biology or immuno-chromatography techniques, acting as an initial diagnostic step in the process.


Subject(s)
Anti-Bacterial Agents , Bacterial Proteins , Gram-Negative Bacteria , Microbial Sensitivity Tests , beta-Lactamases , beta-Lactamases/analysis , beta-Lactamases/metabolism , Bacterial Proteins/metabolism , Gram-Negative Bacteria/enzymology , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/classification , Humans , Anti-Bacterial Agents/pharmacology , Sensitivity and Specificity , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/diagnosis , Imipenem/pharmacology
7.
Braz J Microbiol ; 55(3): 2071-2083, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38904690

ABSTRACT

Co-infection of Lactococcus garvieae and Aeromonas hydrophila, has been confirmed from diseased Nile Tilapia (Oreochromis niloticus), Chithralada strain cultured in a freshwater rearing pond of Alappuzha district of Kerala, India. The aetiological agents behind the disease outbreak were bacteriologically proven and confirmed by 16SrRNA sequencing and phylogenetic analysis. PCR detection of the virulent genes, showed existence of adhesin and hemolysin in L. garvieae and aerolysin in A. hydrophila strain obtained. To fulfil Koch's postulates, challenge experiments were conducted and median lethal dose (LD50) of L. garvieae and A. hydrophila was calculated as 1 × 105.91 CFU per mL and 1 × 105.2 CFU per mL respectively. Histopathologically, eyes, spleen, and kidney were the predominantly infected organs by L. garvieae and A. hydrophila. Out of the 13 antibiotics tested to check antibiotic susceptibility, L. garvieae showed resistance to almost 7 antibiotics tested, with a resistance to Ciprofloxacin while A. hydrophila was found resistant to Streptomycin and Erythromycin. Understanding the complex interaction between Gram-positive and Gram-negative bacteria in the disease process and pathogenesis in fish host will contribute to efficient treatment strategies. As a preliminary investigation into this complex interaction, the present study is aimed at phenotypic and genotypic characterization, pathogenicity evaluation, and antibiotic susceptibility of the co-infecting pathogens in a diseased sample of freshwater-farmed Nile tilapia.


Subject(s)
Aeromonas hydrophila , Anti-Bacterial Agents , Cichlids , Coinfection , Fish Diseases , Gram-Negative Bacterial Infections , Lactococcus , Phylogeny , Animals , Aeromonas hydrophila/genetics , Aeromonas hydrophila/isolation & purification , Aeromonas hydrophila/pathogenicity , Aeromonas hydrophila/classification , Aeromonas hydrophila/drug effects , Cichlids/microbiology , India , Fish Diseases/microbiology , Lactococcus/genetics , Lactococcus/isolation & purification , Lactococcus/classification , Lactococcus/pathogenicity , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/veterinary , Coinfection/microbiology , Coinfection/veterinary , Anti-Bacterial Agents/pharmacology , Microbial Sensitivity Tests , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/veterinary , RNA, Ribosomal, 16S/genetics , Aquaculture , Hemolysin Proteins/genetics , Hemolysin Proteins/metabolism
9.
Ann Clin Microbiol Antimicrob ; 23(1): 43, 2024 May 10.
Article in English | MEDLINE | ID: mdl-38730467

ABSTRACT

BACKGROUND: Shewanella putrefaciens is a gram-negative, nonfermenting, oxidase-positive, hydrogen sulfide-producing bacillus and a halophilic bacterium, known for causing unusual infections in humans and often regarded as an opportunistic pathogen. Its diverse symptoms have a significant impact on human health, with 260 documented disorders reported in the literature over the last 40 years, highlighting its potential danger. CASE PRESENTATION: We present the case of a previously healthy 15-year-old male patient who sustained a self-inflicted sharp-object injury while working in the field, resulting in secondary septic monoarthritis due to Shewanella putrefaciens. CONCLUSIONS: This case highlights the bacteriological and clinical characteristics, as well as the antibiogram, of Shewanella spp. Given the recent increase in notifications of Shewanella infections, predominantly by S. algae and S. putrefaciens, it is essential to consider these pathogens in patients with a history of contact with bodies of water. Special attention must be paid to their resistance patterns in patient management to prevent the development of intrinsic antimicrobial resistance.


Subject(s)
Anti-Bacterial Agents , Arthritis, Infectious , Gram-Negative Bacterial Infections , Shewanella putrefaciens , Humans , Shewanella putrefaciens/isolation & purification , Male , Adolescent , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/drug therapy , Arthritis, Infectious/microbiology , Arthritis, Infectious/drug therapy , Anti-Bacterial Agents/therapeutic use , Microbial Sensitivity Tests , Knee Joint/microbiology
10.
Int J Antimicrob Agents ; 64(2): 107203, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38763452

ABSTRACT

BACKGROUND: There was a reported increase in the antimicrobial consumption in hospitals during the COVID-19 pandemic, accompanied by an increase in infections due to multidrug-resistant (MDR) bacteria. METHODS: This retrospective time series study from intensive care units in Buenos Aires examined changes in antibiotic consumption (defined daily doses/1000 patients/day), the incidence of Gram-negative bacilli (GNB) and the mechanism of resistance. Antibiotics were categorised into group 1 (agents against MDR GNB) and group 2 (agents against non-MDR infections). Bacteriological samples included respiratory samples and blood cultures. Periods were divided into pre-pandemic (July 2019 to March 2020) and pandemic (April 2020 to March 2022). Correlation coefficients (r) were analysed and the Mann-Whitney test was performed to compare both periods. RESULTS: During the study period, GNB incidence, group 1 antibiotic consumption and resistance mechanisms increased, whereas antibiotics decreased in group 2. A significant positive correlation was seen between the consumption of antibiotics in group 1 and the incidence of GNB (r = 0.63; P < 0.001) and resistance (r = 0.52; P = 0.002). Significant differences were found between pre-pandemic and pandemic periods regarding the medians of group 1 consumption (520 [408-570] vs. 753 [495-851] DDD/1000 patients/day; P = 0.029), incidence of GNB (12 [10-13] vs. 43 [25-52.5] cases/month; P < 0.001) and resistance mechanisms (5 [4-8] vs. 17 [10-25] cases/month; P < 0.001), extended-spectrum beta lactamases (2 [1-2] vs. 6 [3-8] cases/month; P < 0.001) and metallo-beta-lactamases (0 [0-0] vs. 6 [1.75-8.5] cases/month; P < 0.001). CONCLUSION: During the COVID-19 pandemic, the rise in GNB incidence and the amount of resistance mechanisms significantly correlated with the increase in consumption of agents against MDR strains.


Subject(s)
Anti-Bacterial Agents , COVID-19 , Gram-Negative Bacteria , Intensive Care Units , Humans , COVID-19/epidemiology , Retrospective Studies , Anti-Bacterial Agents/therapeutic use , Incidence , Argentina/epidemiology , Gram-Negative Bacteria/drug effects , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology , SARS-CoV-2/drug effects , Drug Resistance, Multiple, Bacterial
11.
Braz J Microbiol ; 55(3): 3031-3035, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38809496

ABSTRACT

Stenotrophomonas maltophilia (S. maltophilia) is an intrinsically drug-resistant and biofilm-forming bacteria causing infections in immunocompromised humans. This study reports the isolation of five S. maltophilia strains from saliva and gingival crevicular fluid (GCF) of AIDS patients with periodontitis in São Paulo, Brazil, showing resistance to ceftazidime, strong biofilm formation capacity and a close genetic relationship. The presence of S. maltophilia strains in saliva and CGF of patients with AIDS and periodontitis is a concern for the presence and persistence of intrinsically resistant bacteria in the oral environment, enhancing the risk for the development of severe infections in immunocompromised patients.


Subject(s)
Acquired Immunodeficiency Syndrome , Anti-Bacterial Agents , Biofilms , Ceftazidime , Gingival Crevicular Fluid , Gram-Negative Bacterial Infections , Periodontitis , Saliva , Stenotrophomonas maltophilia , Humans , Stenotrophomonas maltophilia/drug effects , Stenotrophomonas maltophilia/genetics , Stenotrophomonas maltophilia/isolation & purification , Brazil , Saliva/microbiology , Periodontitis/microbiology , Gingival Crevicular Fluid/microbiology , Gingival Crevicular Fluid/chemistry , Ceftazidime/pharmacology , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacterial Infections/microbiology , Biofilms/growth & development , Biofilms/drug effects , Acquired Immunodeficiency Syndrome/microbiology , Male , Adult , Female , Microbial Sensitivity Tests , Drug Resistance, Bacterial , Middle Aged
12.
Microbiol Spectr ; 12(6): e0171423, 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38629835

ABSTRACT

In this study, the genetic differences and clinical impact of the carbapenemase-encoding genes among the community and healthcare-acquired infections were assessed. This retrospective, multicenter cohort study was conducted in Colombia and included patients infected with carbapenem-resistant Gram-negative rods between 2017 and 2021. Carbapenem resistance was identified by Vitek, and carbapenemase-encoding genes were identified by whole-genome sequencing (WGS) to classify the alleles and sequence types (STs). Descriptive statistics were used to determine the association of any pathogen or gene with clinical outcomes. A total of 248 patients were included, of which only 0.8% (2/248) had community-acquired infections. Regarding the identified bacteria, the most prevalent pathogens were Pseudomonas aeruginosa and Klebsiella pneumoniae. In the WGS analysis, 228 isolates passed all the quality criteria and were analyzed. The principal carbapenemase-encoding gene was blaKPC, specifically blaKPC-2 [38.6% (88/228)] and blaKPC-3 [36.4% (83/228)]. These were frequently detected in co-concurrence with blaVIM-2 and blaNDM-1 in healthcare-acquired infections. Notably, the only identified allele among community-acquired infections was blaKPC-3 [50.0% (1/2)]. In reference to the STs, 78 were identified, of which Pseudomonas aeruginosa ST111 was mainly related to blaKPC-3. Klebsiella pneumoniae ST512, ST258, ST14, and ST1082 were exclusively associated with blaKPC-3. Finally, no particular carbapenemase-encoding gene was associated with worse clinical outcomes. The most identified genes in carbapenemase-producing Gram-negative rods were blaKPC-2 and blaKPC-3, both related to gene co-occurrence and diverse STs in the healthcare environment. Patients had several systemic complications and poor clinical outcomes that were not associated with a particular gene.IMPORTANCEAntimicrobial resistance is a pandemic and a worldwide public health problem, especially carbapenem resistance in low- and middle-income countries. Limited data regarding the molecular characteristics and clinical outcomes of patients infected with these bacteria are available. Thus, our study described the carbapenemase-encoding genes among community- and healthcare-acquired infections. Notably, the co-occurrence of carbapenemase-encoding genes was frequently identified. We also found 78 distinct sequence types, of which two were novel Pseudomonas aeruginosa, which could represent challenges in treating these infections. Our study shows that in low and middle-income countries, such as Colombia, the burden of carbapenem resistance in Gram-negative rods is a concern for public health, and regardless of the allele, these infections are associated with poor clinical outcomes. Thus, studies assessing local epidemiology, prevention strategies (including trials), and underpinning genetic mechanisms are urgently needed, especially in low and middle-income countries.


Subject(s)
Anti-Bacterial Agents , Bacterial Proteins , Gram-Negative Bacteria , Gram-Negative Bacterial Infections , Pseudomonas aeruginosa , beta-Lactamases , Humans , Colombia/epidemiology , beta-Lactamases/genetics , beta-Lactamases/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Retrospective Studies , Male , Female , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/epidemiology , Middle Aged , Gram-Negative Bacteria/genetics , Gram-Negative Bacteria/enzymology , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/classification , Anti-Bacterial Agents/pharmacology , Pseudomonas aeruginosa/genetics , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/enzymology , Adult , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Microbial Sensitivity Tests , Aged , Cross Infection/microbiology , Cross Infection/epidemiology , Carbapenems/pharmacology , Community-Acquired Infections/microbiology , Community-Acquired Infections/epidemiology , Whole Genome Sequencing , Adolescent , Young Adult
13.
An Acad Bras Cienc ; 96(1): e20230188, 2024.
Article in English | MEDLINE | ID: mdl-38597489

ABSTRACT

The growing increase in the fish farming sector has favored the establishment of bacterial outbreaks caused by Aeromonas hydrophila in several species. The hexane extract of Hesperozygis ringens (HEHR) (Lamiaceae) leaves increased the survival rate of silver catfish (Rhamdia quelen) experimentally infected by A. hydrophila. However, it is noteworthy that no reports have been found on the possible mechanisms of action of this extract in infected fish. This study aimed to evaluate the effect of the HEHR, administered through single immersion bath, on lipid peroxidation and antioxidant defenses in muscle and liver tissue of silver catfish challenged with A. hydrophila. The results showed that the oxidative status of silver catfish was altered, although oxidative stress was not triggered during the experiment. HEHR at 30 mg/L (HEHR30) was not characterized as a pro-oxidant agent in the presence of infection, unlike florfenicol and HEHR at 15 mg/L treatments in some cases. In short, HEHR30 provided an important increase in hepatic catalase activity, characterizing one of the possible mechanisms involved in the greater survival of fish experimentally infected by A. hydrophila. Additionally, HEHR30 did not induce lipid peroxidation, nor reduced antioxidant defenses of silver catfish infected or not by A. hydrophila.


Subject(s)
Catfishes , Fish Diseases , Gram-Negative Bacterial Infections , Lamiaceae , Animals , Aeromonas hydrophila , Antioxidants/pharmacology , Hexanes , Immersion , Oxidation-Reduction , Fish Diseases/drug therapy , Fish Diseases/microbiology , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/veterinary , Gram-Negative Bacterial Infections/microbiology
14.
Diagn Microbiol Infect Dis ; 109(2): 116235, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38458096

ABSTRACT

OBJECTIVES: Ceftazidime-avibactam (CAZ-AVI) is an option for infections caused by MDR gram-negative bacilli. In this study, we aimed to analyze the in vitro antimicrobial activity of CAZ-AVI and other antimicrobial agents against gram-negative bacilli that were collected in Colombia between 2019 and 2021 from patients with bacteremia and skin and soft-tissue infections (SSTIs). METHODS: A total of 600 Enterobacterales and 259 P. aeruginosa strains were analyzed. The phenotypic resistance of isolates, particularly non-susceptibility to meropenem, multidrug-resistant (MDR) isolates, and difficult-to-treat (DTR) P. aeruginosa, was evaluated according to CLSI breakpoints. RESULTS: Enterobacterales had the most susceptibility to CAZ-AVI (96.5 %) and tigecycline (95 %). Tigecycline and CAZ-AVI were the antimicrobial agents with the most in vitro activity against carbapenem-resistant Enterobacterales (CRE). CAZ-AVI was the antimicrobial treatment with the most activity against P. aeruginosa. CONCLUSIONS: Tigecycline and CAZ-AVI were the antimicrobial agents with the most activity against CRE and MDR Enterobacterales. For P. aeruginosa, CAZ-AVI was the antimicrobial treatment with the most in vitro activity.


Subject(s)
Anti-Bacterial Agents , Azabicyclo Compounds , Bacteremia , Ceftazidime , Drug Combinations , Gram-Negative Bacteria , Microbial Sensitivity Tests , Soft Tissue Infections , Tigecycline , Humans , Ceftazidime/pharmacology , Soft Tissue Infections/microbiology , Soft Tissue Infections/drug therapy , Colombia , Azabicyclo Compounds/pharmacology , Anti-Bacterial Agents/pharmacology , Bacteremia/microbiology , Bacteremia/drug therapy , Gram-Negative Bacteria/drug effects , Tigecycline/pharmacology , Pseudomonas aeruginosa/drug effects , Drug Resistance, Multiple, Bacterial , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/drug therapy , Enterobacteriaceae/drug effects , Skin Diseases, Bacterial/microbiology , Skin Diseases, Bacterial/drug therapy
15.
Rev. ADM ; 81(1): 39-43, ene.-feb. 2024. tab
Article in Spanish | LILACS | ID: biblio-1556339

ABSTRACT

Introducción: la persistencia de microorganismos en los conductos radiculares es uno de los principales factores del fracaso endodóncico. Por ello la importancia de conocer las propiedades antimicrobianas de los distintos tipos de selladores. Objetivo: realizar una comparación con base en la evidencia disponible sobre la actividad antimicrobiana de los diferentes cementos selladores en endodoncia. Material y métodos: la información fue recopilada de las bases de datos PubMed y Google Académico en el idioma inglés y español, publicados en el periodo 2014-2023. Resultados: un gran número de microorganismos se encuentran presentes en los diferentes tipos de infecciones de origen endodóncico, se han identificado más de 500 especies microbianas, entre ellas bacterias, hongos, arqueas y virus. Los cementos selladores se pueden clasificar según su composición química, en cementos a base de óxido de zinc-eugenol, hidróxido de calcio, a base de ionómero de vidrio, silicona, resina y biocerámicos. Conclusión: los cementos selladores que mostraron mayor actividad antimicrobiana contra los microorganismos persistentes fueron los cementos a base de óxido de zinc-eugenol, resina y biocerámicos. Sin embargo, se identificó que cada autor utilizó diferentes métodos y tiempos, por lo tanto, no es posible lograr definir con exactitud qué cemento sellador posee la mejor capacidad antimicrobiana (AU)


Introduction: the persistence of microorganisms in root canals is one of the main factors of endodontic failure. Therefore, the importance of knowing the antimicrobial properties of the different types of sealants. Objective: to make a comparison based on the available evidence on the antimicrobial activity of the different endodontics sealers. Material and methods: the information was collected from PubMed and Google Academic databases in English and Spanish, published in the period 2014-2023. Results: a large number of microorganisms are present in the different types of infections of endodontic origin, more than 500 microbiological species have been identified, including bacteria, fungi, archaea and viruses. Sealer cements can be classified according to their chemical composition, into cements based on zinc oxide-eugenol, calcium hydroxide, based on glass ionomer, silicone, resin and bioceramics. Conclusion: sealer cements that showed the highest antimicrobial activity against persistent microorganisms were zinc oxide-eugenol, resin, and bioceramic-based cements. However, it was identified that each author used different methods and times, therefore, it is not possible to accurately define which sealer cement has the best antimicrobial capacity (AU)


Subject(s)
Root Canal Filling Materials/chemistry , Dental Pulp Cavity/microbiology , Zinc Oxide-Eugenol Cement/chemistry , Calcium Hydroxide/chemistry , Databases, Bibliographic , Gram-Positive Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/microbiology , Resin Cements/chemistry , Organically Modified Ceramics/chemistry , Glass Ionomer Cements/chemistry , Anti-Bacterial Agents/pharmacology
16.
Jpn J Infect Dis ; 77(4): 213-219, 2024 Jul 23.
Article in English | MEDLINE | ID: mdl-38296539

ABSTRACT

Stenotrophomonas maltophilia is a nonfermenting Gram-negative drug-resistant pathogen that causes healthcare-associated infections. Clinical isolates from Mexico were assessed for biofilm formation using crystal violet staining. Antimicrobial susceptibility was evaluated in planktonic and biofilm cells using the broth microdilution method. The effects of antibiotics on biofilms were visualized using fluorescence microscopy. Fifty isolates were included in this study, of which 14 (28%) were biofilm producers (9 [64%] from blood and 5 [36%] from respiratory samples). In planktonic cells 4/50 (8%) of isolates were resistant to levofloxacin (8.0%) and 22/50 (44%) were resistant to trimethoprim-sulfamethoxazole. All isolates were resistant to levofloxacin and trimethoprim-sulfamethoxazole in biofilm cells. Bacterial biofilms treated with different concentrations of both antibiotics were completely disrupted. In conclusion, S. maltophilia isolated from blood had higher biofilm production than those isolated from respiratory samples. Biofilm production was associated with increased antibiotic resistance. Antibiotic monotherapy might not be the best course of action for the treatment of S. maltophilia infections in Mexico, because it might cause biofilm production and antimicrobial resistance.


Subject(s)
Anti-Bacterial Agents , Biofilms , Gram-Negative Bacterial Infections , Levofloxacin , Microbial Sensitivity Tests , Stenotrophomonas maltophilia , Trimethoprim, Sulfamethoxazole Drug Combination , Stenotrophomonas maltophilia/drug effects , Biofilms/drug effects , Biofilms/growth & development , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology , Levofloxacin/pharmacology , Humans , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/microbiology , Mexico , Microscopy, Fluorescence
17.
Curr Microbiol ; 81(1): 20, 2023 Nov 26.
Article in English | MEDLINE | ID: mdl-38008776

ABSTRACT

Stenotrophomonas maltophilia is an opportunistic human pathogen associated with nosocomial and community-acquired infections. We have conducted a microbiological and genomic surveillance study of broad-spectrum cephalosporin- and carbapenem-resistant Gram-negative bacteria colonizing wild birds inhabiting the Brazilian Amazonia. Strikingly, two S. maltophilia strains (SM79 and SM115) were identified in Plain-throated antwren (Isleria hauxwelli) passerines affected by Amazonian fragmentation and degradation. Noteworthy, SM79 and SM115 strains belonged to new sequence types (STs) ST474 and ST473, respectively, displaying resistance to broad-spectrum ß-lactams, aminoglycosides and/or fluoroquinolones. In this regard, resistome analysis confirmed efflux pumps (smeABC, smeDEF, emrAB-tolC and macB), blaL1 and blaL2, aph(3')-IIc and aac(6')-Iak, and Smqnr resistance genes. Comparative phylogenomic analysis with publicly available S. maltophilia genomes clustered ST473 and ST474 with human strains, whereas the ST474 was also grouped with S. maltophilia strains isolated from water and poultry samples. In summary, we report two novel sequence types of S. maltophilia colonizing wild Amazonian birds. The presence of opportunistic multidrug-resistant pathogens in wild birds, from remotes areas, could represent an ecological problem since these animals could easily promote long-distance dispersal of medically important antimicrobial-resistant bacteria. Therefore, while our results could provide a baseline for future epidemiological genomic studies, considering the limited information regarding S. maltophilia circulating among wild animals, additional studies are necessary to evaluate the clinical impact and degree of pathogenicity of this human opportunistic pathogen in wild birds.


Subject(s)
Gram-Negative Bacterial Infections , Stenotrophomonas maltophilia , Humans , Animals , Stenotrophomonas maltophilia/genetics , Brazil , Animals, Wild , Microbial Sensitivity Tests , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacterial Infections/veterinary , Gram-Negative Bacterial Infections/microbiology
18.
J Appl Microbiol ; 134(10)2023 Oct 04.
Article in English | MEDLINE | ID: mdl-37838475

ABSTRACT

AIMS: Evaluate methods for identification and typing of Stenotrophomonas maltophilia isolated from a pharmaceutical facility. METHODS AND RESULTS: From 270 S. maltophilia strains identified by VITEK®2, 40 were selected and submitted to MALDI TOF-MS, 16S and 23S rRNA gene analysis, enterobacterial repetitive intergenic consensus-polymerase chain reaction (ERIC-PCR), and an antimicrobial susceptibility profile. 16S rRNA sequencing was able to identify 39 (97.5%) strains as Stenotrophomonas spp. and one (2.5%) as Luteimonas huabeiensis. MALDI TOF-MS identified 37 (92.5%) strains as S. maltophilia, and three (7.5%) were not identified. PCR targeting 23S rRNA yielded a positive result for 39 (97.5%) strains. However, after sequencing, two strains were identified as Stenotrophomonas rhizophila, showing false-positive results. The confirmed S. maltophilia strains (n = 37) showed 35 distinct ERIC-PCR profiles and exhibited sensitivity to minocycline and levofloxacin, and six (16.3%) showed intermediate resistance to sulfamethoxazole-trimethoprim. CONCLUSION: Matrix-assisted laser desorption lonization-time of flight mass spectrometry (MALDI-TOF MS) was a satisfactory methodology for the identification of S. maltophilia, but expansion of the database is necessary for the identification of other species. 16S rDNA sequencing showed low resolution for Stenotrophomonas species differentiation. PCR targeting 23S rRNA could not differentiate S. maltophilia from S. rhizophila. ERIC-PCR was shown to be a useful tool for the microbial source tracking of S. maltophilia.


Subject(s)
Gram-Negative Bacterial Infections , Stenotrophomonas maltophilia , Humans , Stenotrophomonas maltophilia/genetics , RNA, Ribosomal, 16S/genetics , Trimethoprim, Sulfamethoxazole Drug Combination , Minocycline , Levofloxacin , Gram-Negative Bacterial Infections/microbiology , Anti-Bacterial Agents/pharmacology , Microbial Sensitivity Tests
19.
Am J Trop Med Hyg ; 109(5): 1095-1106, 2023 11 01.
Article in English | MEDLINE | ID: mdl-37722663

ABSTRACT

Surveillance of antimicrobial resistance among gram-negative bacteria (GNB) is of critical importance, but data for Peru are not available. To fill this gap, a non-interventional hospital-based surveillance study was conducted in 15 hospitals across Peru from July 2017 to October 2019. Consecutive unique blood culture isolates of key GNB (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter spp.) recovered from hospitalized patients were collected for centralized antimicrobial susceptibility testing, along with linked epidemiological and clinical data. A total of 449 isolates were included in the analysis. Resistance to third-generation cephalosporins (3GCs) was present in 266 (59.2%) GNB isolates. Among E. coli (n = 199), 68.3% showed 3GC resistance (i.e., above the median ratio for low- and middle-income countries in 2020 for this sustainable development goal indicator). Carbapenem resistance was present in 74 (16.5%) GNB isolates, with wide variation among species (0% in E. coli, 11.0% in K. pneumoniae, 37.0% in P. aeruginosa, and 60.8% in Acinetobacter spp. isolates). Co-resistance to carbapenems and colistin was found in seven (1.6%) GNB isolates. Empiric treatment covered the causative GNB in 63.3% of 215 cases. The in-hospital case fatality ratio was 33.3% (92/276). Pseudomonas aeruginosa species and carbapenem resistance were associated with higher risk of in-hospital death. In conclusion, an important proportion of bloodstream infections in Peru are caused by highly resistant GNB and are associated with high in-hospital mortality.


Subject(s)
Gram-Negative Bacterial Infections , Sepsis , Humans , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Escherichia coli , Prevalence , Peru/epidemiology , Hospital Mortality , Drug Resistance, Bacterial , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology , Carbapenems , Gram-Negative Bacteria , Klebsiella pneumoniae , Pseudomonas aeruginosa , Sepsis/drug therapy , Microbial Sensitivity Tests
20.
Trop Anim Health Prod ; 55(5): 289, 2023 Aug 15.
Article in English | MEDLINE | ID: mdl-37580646

ABSTRACT

The pirarucu (Arapaima gigas) is a fast-growing Amazonian species of high commercial value. The present study aimed to determine the dietary crude protein (CP) level to promote maximum zootechnical performance for pirarucu fingerlings and as their resistance to Aeromonas hydrophila, as well as evaluate their hematological parameters. Pirarucu fingerlings (2.4 ± 0.08 g, 6.8 ± 0.52 cm) were distributed in 18 tanks (140 L, 40 fish per tank, n = 3) and fed six experimental diets consisting of increasing levels of CP: 300, 400, 450, 500, 550 and 650 g kg-1 in a completely randomized design. Data were submitted to one-way ANOVA (p < 0.05) and the ideal CP level for weight gain was determined using polynomial regression analysis. The dietary CP levels were evaluated using a quadratic polynomial regression and the level of 595 g kg-1 was determined for the best weight gain. The hematocrit of fish fed 300 g kg-1 was higher than in the other groups. No mortalities were observed after the 15-day bacterial challenge; however, number of pirarucu with bacterial damage on the pirarucu caudal fin was higher in the group that was fed the diet with 300 g kg-1. A dietary protein level of 618 g kg-1 is therefore recommended for providing maximum weight gain and immunological resistance in pirarucu fingerlings weighing 2.4-112.5 g.


Subject(s)
Aeromonas hydrophila , Gram-Negative Bacterial Infections , Animals , Aeromonas hydrophila/physiology , Animal Feed/analysis , Diet/veterinary , Dietary Proteins , Dietary Supplements/analysis , Fishes/physiology , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/veterinary , Hematocrit/veterinary
SELECTION OF CITATIONS
SEARCH DETAIL